On May 28, 2026 Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, reported Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York City, NY on Thursday, June 4 at 8:10 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

(Press release, Whitehawk Therapeutics, MAY 28, 2026, View Source [SID1234666161])

On May 28, 2026 Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), reported the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The strategic collaboration brings together Innovent’s scientific discovery and clinical capabilities in oncology innovation with Pfizer’s deep scientific expertise, global clinical development capabilities, regulatory leadership and commercial scale, which are highly complementary to each company’s core areas of interest.

The agreement spans a portfolio of 12 programs comprising eight Innovent-originated early-stage programs and four Pfizer-proposed discovery programs. The companies will co-develop and share costs for select programs as they advance these programs through clinical development.

"This agreement brings together best-in-industry expertise of Pfizer and Innovent to advance novel cancer medicines to patients at a global scale," said Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent. "By leveraging both companies’ complementary resources, we can develop our early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide. Furthermore, co-developing and co-commercializing key projects in the U.S. and Europe expands Innovent’s global reach. At Innovent, we are laying the foundation for a truly global oncology platform that can deliver meaningful and lasting benefits for patients around the world."

"At Pfizer, everything we do starts with patients and the urgency to change what’s possible for people living with cancer," said Jeff Legos, Chief Oncology Officer, Pfizer. "This collaboration brings together two highly complementary engines of innovation with a shared ambition to move faster, go further and deliver truly transformative medicines to patients who are waiting. By combining Innovent’s discovery and early clinical development with Pfizer’s global research and development and commercialization capabilities, we have an opportunity not only to strengthen our pipeline, but to accelerate the delivery of breakthroughs that can redefine standards of care and make a meaningful difference in patients’ lives."

According to the agreement, Innovent will conduct development of these programs through Phase 1, powered by its proprietary discovery engine and robust early clinical capabilities, after which Pfizer will lead future global development. The agreement also sets out the following licensing and commercialization structure:

Innovent and Pfizer will co-develop four programs globally and share the development costs. The companies will co-commercialize in the United States and Europe*, and share the profits. Innovent will retain Greater China rights to these programs.
Pfizer will receive an exclusive license outside Greater China for four programs, and will be responsible for the majority of the development costs; and
Pfizer will receive an exclusive global license for four programs, and will be responsible for the global development costs.
Under the financial terms of the agreement, Innovent will receive a $650 million upfront payment and is eligible for up to $9.85 billion in development, regulatory and commercial milestone payments, bringing the total value of the deal to up to $10.5 billion. Additionally, Innovent will receive up to double-digit royalties on sales of each licensed product if approved. For the ‘co-developed, co-commercialized’ programs, the two companies will share the profits in the U.S. and Europe.

The closing of the transaction is subject to fulfillment of required regulatory approvals.

(Press release, Innovent Biologics, MAY 28, 2026, View Source [SID1234666160])

On May 28, 2026 Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, reported updated positive Phase 2 results of spevatamig (PT886) in combination with chemotherapy in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) for the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2026 . The full poster presentation will be held on Saturday, May 30 between 9am-12pm CDT during the Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary Session (Abstract #4192, Poster #175).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy, has the potential to be an effective 1L treatment in patients with metastatic PDAC (mPDAC).

The design of spevatamig with an optimized anti-CD47 arm mitigates hematological toxicity and improves GI tolerability, as evidenced by the results of the spevatamig monotherapy and combination therapy studies where >190 patients have been dosed globally.

Spevatamig + GnP combination is well tolerated in 1L patients with mPDAC, with no significant additive toxicity to GnP.

2 mg/kg QW spevatamig + GnP showed promising efficacy (52.4% ORR, 90.5% DCR) when compared with the GnP arm in pivotal trials in 1L mPDAC; importantly, more than 90% of patients at this dose level had de novo metastatic disease, consistent with the baseline characteristics of the patient populations in pivotal Phase 3 trials.

Median progression-free survival (mPFS) was 7.3 months, and median overall survival (mOS) was 14.7 months in US patients, where the median follow up time is 14.7 months.

The efficacy data for 3 mg/kg spevatamig + GnP is still maturing. 3 mg/kg has the potential to be the dose level for a Phase 3 registrational study.

Overall, the data support further development of spevatamig + GnP in a randomized Phase 3 trial in patients with 1L mPDAC.
Spevatamig is an innate immunity enhancer (I2E), an emerging class of immuno-oncology (IO) agents. Unlike immune checkpoint inhibitors (ICIs) (also known as anti-PD1/anti-PD-L1 drugs) which activate T cells to kill cancer cells, I2Es activate macrophages and dendritic cells to recognize and destroy cancer cells, providing an alternative mechanism to leverage the immune system to attack tumors, especially the so-called "cold tumors" that do not respond to ICIs.

"We are pleased to see the positive results at the first dose level of spevatamig in the 1L PDAC study. This result is significant because PDAC is considered a ‘cold tumor’ to ICIs. Now we have the opportunity to target PDAC with a new class of immunotherapy," said Ming Wang, PhD, MBA, Founder and CEO of Phanes. "The enrollment at the 3 mg/kg dose level is progressing rapidly and we hope to see efficacy data in the second half of 2026. We could be Phase 3 ready shortly after that. Our goal is to advance this exciting I2E aggressively and deliver an innovative immunotherapy for patients with mPDAC."

ABOUT SPEVATAMIG

Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. In 2023, Phanes entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to study spevatamig in combination with pembrolizumab.

Phanes is conducting clinical trials with spevatamig in multiple cancer indications, including a Phase 2 study evaluating the efficacy of spevatamig in combination with chemotherapy in first-line PDAC patients. Spevatamig is a novel immunotherapy which has the potential to become the first innate immunity enhancer (I2E) for a solid tumor indication and is combinable with various anti-cancer therapies.

(Press release, Phanes Therapeutics, MAY 28, 2026, View Source [SID1234666159])

On May 28, 2026 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the "Investors" section of Akebia’s website at View Source A replay of the webcast will also be available for 90 days following the presentation.

The 2026 Jefferies Global Healthcare Conference will take place June 2-4, 2026, in New York, NY.

(Press release, Akebia, MAY 28, 2026, View Source [SID1234666158])

On May 28, 2026 Sapu Nano and Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") reported that Vuong Trieu, Chief Executive Officer, reported it will present the Company’s Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will focus on Oncotelic’s development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics that are otherwise difficult or impossible to formulate using conventional technologies.

The Deciparticle platform is based on proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The Company believes the platform may enable improved aqueous compatibility, reduced reliance on toxic excipients, enhanced manufacturability, and broader development flexibility for challenging compounds.

At BIO 2026, the Company plans to highlight development progress across multiple Deciparticle programs, including:

Sapu006, a polysorbate-free intravenous docetaxel formulation currently moving into Phase 1b clinical evaluation;
Sapu003, an intravenous everolimus nanomedicine program designed to potentially reduce gastrointestinal exposure associated with oral administration currently in a global Phase 1b clinical trial; and
Broader applications of the Deciparticle platform for difficult-to-formulate small molecules and macrolide therapeutics.
The Company will also discuss how artificial intelligence and knowledge-organization technologies are being integrated into formulation development, manufacturing intelligence, and translational oncology workflows through its PDAOAI platform.

"Many important therapeutics remain limited by formulation complexity, poor aqueous solubility, excipient-related toxicity, or manufacturing challenges," said Vuong Trieu, Chief Executive Officer. "Our objective with Deciparticle is to create a scalable nanomedicine platform capable of enabling intravenous delivery of highly insoluble molecules while simplifying formulation architecture and supporting clinical translation."

According to the Company, Deciparticle formulations are designed to address key limitations associated with conventional solubilizing systems, including hypersensitivity reactions, surfactant burden, formulation instability, and manufacturing complexity.

Oncotelic believes the combination of nanomedicine engineering, translational oncology, manufacturing expertise, and AI-driven scientific cognition may provide a differentiated platform for future drug development.

BIO International Convention is one of the biotechnology industry’s largest partnering and innovation events, bringing together biotechnology companies, pharmaceutical companies, investors, and scientific leaders from around the world.

About Deciparticle

Deciparticle is Oncotelic’s proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.

(Press release, Oncotelic, MAY 28, 2026, View Source [SID1234666157])